Kornimate/medical-research-clean huggingface dataset:
fibromyalgia syndrome on patients with chronic migraine

Conditions: Chronic Migraine, Headache; Fibromyalgia Syndrome; Chronic Pain Syndrome; Central Sensitisation; Headache Disorders

Summary: the aim of this study to evaluate the effects of fibromyalgia syndrome accompanying women with chronic migraine on pain, quality of life, sleep, anxiety and depression, central sensitization and functionality.

patients who applied to istanbul university-cerrahpaşa, cerrahpaşa faculty of medicine, department of neurology, headache outpatient clinic and were diagnosed with chronic migraine according to the international headache society classification (ichd-3), after the patient's history and physical examination, will be included in the study. date of birth, education level, body mass index, occupation, marital status, socioeconomic status, age of onset of migraine complaints, descriptive information about migraine attacks (type (with or without aura), duration of attacks, average number of days with pain, pain severity, accompaniments) will be questioned. in addition, if the fibromyalgia syndrome meets the diagnostic criteria, symptom duration and average body pain severity in the last 3 months will be questioned. a total of 66 patients are planned to be included in the study. in the study, 2 groups will be formed, the first group will consist of chronic migraine patients, the second group will consist of patients with chronic migraine as well as fibromyalgia syndrome. all patients will be evaluated for allodynia, quality of life, sleep, anxiety and depression, disability related to headache, and central sensitization. relevant forms will be filled by patients. patients will be evaluated with the diagnostic criteria for fibromyalgia syndrome and if the patients meet the diagnostic criteria for fibromyalgia syndrome, the fibromyalgia impact questionnaire will be applied. the patient will be evaluated by alper mengi in terms of fibromyalgia syndrome diagnostic criteria.

Eligibility criteria:
inclusion criteria: for patients with chronic migraine: * being diagnosed with chronic migraine according to the international headache society classification (ichd-3) * being literate for patients with fibromyalgia syndrome: * diagnosed with chronic migraine according to the international headache society classification (ichd-3) * being literate * diagnosed with fibromyalgia syndrome according to the 2016 american college of rheumatology criteria exclusion criteria: * having another pathology that can explain their pain in the head and face region other than chronic migraine (such as sinusitis, tension-type headache, trigeminal neuralgia, drug overuse headache) * psychiatric disease or using psychiatric drugs * history of serious head trauma or neurosurgical intervention * history of infectious, chronic inflammatory disease, malignancy * pregnant and breastfeeding women * history of additional neurological disease other than migraine * uncooperative * having congestive heart failure, chronic kidney failure, chronic liver disease, lung disease, uncontrolled diabetes, peripheral vascular disease * diagnosed with hypothyroidism or hyperthyroidism
mindfulness based cognitive counseling on social anxiety

Conditions: Social Anxiety; Assertiveness; Self Confidence

Summary: the aim of the study is to determine the effect of group mindfulness based cognitive counseling on social anxiety, assertiveness and self-confidence in nursing students and the relationship of these variables to change over time.

this is a randomized controlled and single-center study. the universe of the research consisted of nursing students who applied for counseling within the scope of the announcement made on the department web page. the research will be carried out in a state university, faculty of health sciences, department of nursing between february 22, 2022 - december 23, 2022. in the study, the assignment of students to the intervention and control groups was made by simple randomization. participant information form, liebowitz social anxiety scale, self-confidence scale and assertiveness inventory will be used to collect the data of the study. data collection tools will be applied three times simultaneously with the control group as a pre-test at the beginning of the study, as a post-test at the last session of the intervention group ( 2 month), and as a follow-up test 6 months after the last session of the intervention group.

Eligibility criteria:
inclusion criteria: * liebowitz social anxiety scale score \>50 * 18 years of age or older * volunteering to participate in the study exclusion criteria: * diagnosed with a mental disorders * history of participating in a counseling program * currently receiving individual or group counseling * unable to attend more than two sessions * diagnosed with a physical or mental disorder during group sessions
nk cell therapy for recurrent glioblastoma multiform patients

Conditions: Glioblastoma Multiform; Recurrent Glioblastoma

Summary: glioblastoma multiform is one of the most invasive and deadly cancers that progresses rapidly and leads to death. surgery with radiotherapy /chemotherapy, as a treatment approach is ineffective in some cases and is associated with relapse and death. immunotherapy is a special strategy that used as an adjunct therapy in various cancers and among the various methods of immunotherapy; it seems that cell therapy with nk cells is of special importance. a previous study conducted at the royan research institute showed that nk cell proliferation and amplification resulted in the removal of glioblastoma tumor masses in the animal model. the animals had no evidence of tumor recurrence after treatment, and all tumor-related complications resolved after treatment. therefore, in this study, the investigators intend to evaluate the safety of ex vivo activated cells in 5 patients with glioblastoma multiform whose disease has returned after treatment and who have not had any appropriate treatment.

1- patient selection 2- leukapheresis 3- cd56+ cells isolation 4- nk cells activation 5- assessment of functionality and purity 6- quality control tests 7-nk cell injection in tumor cavity.

Eligibility criteria:
age: 3-60 year - * sex: both * lansky performance scale/karnofsky performance scale: 70-100% * life span expectation: \>6 months * hemoglobin: \> 10.0 g/dl * platelet count \> 100,000/mm³ * serum total bilirubin \< 1.5 times upper limit of normal (uln) * alt and ast \< 2.5 times uln * serum creatinine \< 1.5 times uln * no diagnosis of any other invasive cancer within the past 5 years. * no concurrent serious medical or psychiatric illness that may interfere with giving informed consent or conducting this study exclusion criteria: * patients whose mri and mrs images is in favor of radio necrosis. * due to emergency conditions, the patient cannot tolerate the new treatment * lack of a suitable donor or insufficient number of nk cells. * development of a new neurological defect after the first injection * patient death during surgery * closing the reservoir for the next injection (if this problem is resolved, the injections will be done again).

Keywords: natural killer cells (nk) glioblastoma multiform (gbm)
tamovalcir in allogenic hematopoietic progenitors transplant

Conditions: Cytomegalovirus Infection

Summary: principal endpoint to value valganciclovir efficacy in advance treatment of cmv in patients received allogenic transplant with a uniform treatment. secondary endpoint to value valganciclovir security in advance treatment of cmv in in patients received allogenic transplant with a uniform treatment. the security will be valued by the % of patients that: will have negative cmv neutropenia \ 1mg/dl or twice the basal value) cmv illness during the treatment or in the next 2 months blood antigenemia / pcr positive in the next 2months of treatment this dates hill be compared with a patients control group treated with intravenous valganciclovir

clinical trial with a drug in new conditions of use

Eligibility criteria:
inclusion criteria: * patients \> 18 years old * any patients with allogenic tph * following in post-tph with antigenemia or pcr-cmv * cmv in blood test detected by antigenemia or pcr before the day 180 post-tph * the beginning of treatment must be duch early as possible. maximum in the 72 hours from the antigenemia or pcr-cmv detection * be the first or second time of a cmv infection * sign the informed consent * pregnancy negative test in fertile age patients exclusion criteria: * patients received auto or syngenic tph * patients \<50 kg weight * known allergy or hypersensibility patients to valganciclovir, ganciclovir or aciclovir * digestive intolerant: nauseous, vomit and or diarrhea that could difficult oral administration of valganciclovir * patients that presents cmv infection or that is being evaluated for suspected cmv * patients that have presented \>2 cmv infection episode, before the current one * severe liver disease defined by bilirubin ≥ 10mg/dl * treated with: foscarnet, ganciclovir, cidofovir or another antiviral drug active to cmv, in the previous 30 days at the current episode * neutrophils \ 500 pmn/µl and \ 1000/µl * platelets \< 25/mm3 even receiving transfusion * clearance creatinine \< 10ml/min or dialysed patients * pregnancy or lactant women * other contraindication detailed in the "filling card" * previous inclusión in this study at the treated group. is allowed that a patient participate as a control case and after that receive valganciclovir treatment in after cmv episode

Keywords: cytomegalovirus infection
long-term study of cp-690,550 in subjects with ulcerative colitis

Conditions: Ulcerative Colitis

Summary: this study is an open label, long-term extension study for subjects with moderate to severe ulcerative colitis designed to evaluate long term therapy of cp-690,550.


Eligibility criteria:
inclusion criteria: * subjects who completed induction studies a3921094 or a3921095 and were classified as not meeting clinical response criteria; or * subjects who completed maintenance study a3921096 or who discontinued treatment early in study a3921096 due to treatment failure. exclusion criteria: * subjects who had a major protocol violation in study a3921094, a3921095 or a3921096. * presence of indeterminate colitis, microscopic colitis, ischemic colitis, infectious colitis, or clinical findings suggestive of crohn's disease. * subjects who have had surgery for ulcerative colitis or in the opinion of the investigator, are likely to require surgery for ulcerative colitis during the study period.

Keywords: ulcerative colitis open-label long term treatment
a study to estimate safety and efficacy of sorafenib (bay43-9006) in the treatment of hepatocellular carcinoma

Conditions: Carcinoma, Hepatocellular

Summary: evaluate anti-cancer activity (e.g. proportion of patients with confirmed complete response or partial response) in patients with advanced, inoperable biopsy-proven hepatocellular carcinoma.

in addition to the key secondary outcome parameters the following exploratory parameters were evaluated in subpopulations: * pharmacokinetics (pk) profile of sorafenib * plasma and tissue tumor biomarkers

Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed primary hepatocellular carcinoma (hcc) * inoperable disease (t2-t4, any n, m0 or m1) or refused surgery * measurable disease * at least 1 bidimensionally measurable lesion of at least 2 cm by computed tomography (ct) scan or magnetic resonance imaging (mri) * presence of at least 1 of the following: * alpha-fetoprotein greater than the upper limit of normal (uln) * hepatitis c antibody positive * hepatitis b surface antigen positive * child's pugh class a or b * candidate for systemic therapy exclusion criteria: * fibrolamellar disease mixed histology * metastatic brain or meningeal tumors

Keywords: cancer liver cancer hepatocellular carcinoma (hcc)
live vaccines and innate immune training in copd.

Conditions: Trained Innate Immunity; COPD

Summary: a randomized, single-blinded clinical pilot study to assess whether vaccination with live attenuated vaccines can induce trained immunity and cause beneficial changes in patients with copd.

single-blinded 1:1:1 block randomized controlled trial (with varying block sizes of 3-6), stratified by sex. a total of 60 participants will be recruited and randomly assigned with 20 in each treatment arm. separated by three months, the participants will receive two doses of one of the following three treatments: 1. mmr vaccine (m-m-r vaxpro) 2. bcg vaccine (danish strain 1331) 3. saline (placebo)

Eligibility criteria:
inclusion criteria: * specialist verified and spirometry-confirmed copd * age \> 40 years. * negative hiv-test. * able to give informed consent. exclusion criteria: * acute febrile illness. * known allergy to bcg or mmr vaccines or serious adverse effects at previous vaccination. * allergy to mmr vaccine components, neomycin, or egg proteins. * known prior, active, or latent infection with mycobacterium tuberculosis. * pregnancy or breastfeeding. * vaccination with a live vaccine within the last 4 weeks. * being severely immunocompromised (hiv-1 infection, organ- or bone marrow transplantation, chemotherapy, primary immune defect, anti-cytokine therapy, immunosuppressant treatment). * oral or intravenous corticosteroid at dose of ≥10 mg/day with duration over 3 months. * active solid or non-solid malignancy or lymphoma, excluding basal cell carcinoma within 2 years. * treatment with immunoglobulins within the last 3 months or expected treatment with immunoglobulins for the duration of the trial.
investigating the impact of jasper behavioral therapy in children with down syndrome

Conditions: Down Syndrome

Summary: in this study, investigators will study the impact of a 1:1 caregiver coaching intervention using the jasper (joint attention, symbolic play, engagement, regulation) behavioral therapy curriculum compared to a psychoeducational curriculum that will be provided to caregivers for self-directed learning. investigators want to determine the impact of both interventions on the child's development and behavior, and caregiver implementation of strategies.

down syndrome (ds), the most common genetic cause of intellectual disability, can be associated with a wide range of developmental needs. behavioral challenges are common, and can impact learning, overall achievement, relationships, inclusion in schools, and community integration. the goal of this study is to determine whether jasper (joint attention symbolic play engagement and regulation) can improve caregiver implementation of behavioral strategies, caregiver self-efficacy and confidence, and child development. participants will be randomized to receive either the jasper intervention or a caregiver psychoeducational group. participants in the jasper intervention will receive 10 weekly virtual educational sessions utilizing jasper therapy modules through 1:1 parent-child coaching sessions. caregivers in the comparison group will receive 10 weekly modules containing a psychoeducational curriculum. the outcome measures will assess caregiver responsiveness, child joint engagement with caregiver, caregiver self-efficacy, and child behavior, language, and adaptive skills.

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of trisomy 21 * age 3-7 years * able to walk independently * english speaking * caregiver able to complete either 1:1 virtual coaching sessions or psychoeducational behavioral curriculum exclusion criteria: * mosaic down syndrome * significant and uncorrected hearing and/or vision problems

Keywords: parent coaching parent education social communication play skills behavioral regulation development emotional regulation
effectiveness of a training protocol with the cervical device in subjects with deep cervical muscle strength deficit.

Conditions: Muscle Weakness; Cervical Disability

Summary: the purpose of this study is to evaluate the clinical results produced by a training protocol with the new device for cervical treatment (cdat) and the conventional training protocol (ct) versus a control group (c) in subjects with cervical deep muscle strength deficit and mild neck disability.

cervical pain is in many cases a decrease in the quality of life.the cervical spine is the most mobile region of the spine which also must be strong enough in order to support the weight of the skull. deficits in deep cervical muscle strength are related to different clinical conditions: cervicogenic dizziness, cervical radiculopathy, cervical mechanical-chronic, cervical pain and cervical instability. training protocols can help to improve pain, cervical function, posture and cross-sectional area. however, there are no training protocols in subjects with mild disability and strength deficit of the deep cervical muscle, including deep neck extensor and flexor muscles. the cervical device treatment (cdat) allows us to train the cervical flexor and extensor muscle in a simple and comfortable way.

Eligibility criteria:
inclusion criteria: * deep flexor strength deficit in craniocervical flexion test. * deep extensor strength deficit in neck extensor muscle endurance test. * ≤ 14 score in neck disability index. exclusion criteria: * have received cervical treatment during the last six month, presented any red flag, neurological or cognitive impairment (inability to understand the questionnaires or examination). * have received cervical manual therapy treatment during the last six month. * a history of cervical trauma or surgery during the last year. * chronic neck pain occurring during the last six months (intensity, visual analogue scale \>3/10, frequency \> 2 days/week, duration \>3 hours/day).

Keywords: neck pain exercise therapy muscle weakness telerehabilitation neck muscles
febuxostat for tumor lysis syndrome prevention in hematological malignancies of paediatric patients and adults

Conditions: Tumor Lysis Syndrome

Summary: the purpose of this study is to compare the exposure of febuxostat in pediatric patients (≥6\<18 years of age) and in adults suffering from hematological malignancies at intermediate to high risk of tls and to compare the effect in terms of serum uric acid levels.

in the floret study it is planned to enroll 3 groups of patients in order to receive oral administration (film-coated tablets) of two different dose levels of febuxostat: children (from 6 to less than 12 years of age) will receive two different dose levels respectively; adolescents (from 12 to less than 18 years of age) will receive 80 and 120 mg/day respectively and adults (equal or major than 18 years of age) will receive 120 mg/day. the two dose levels for children and adolescents groups were to be sequentially administered, whereas the groups that will receive the first dose levels will simultaneously start the treatment at the study beginning. the individual treatment duration will be of 7 to 9 days, according to chemotherapy duration, as per investigator's judgement.

Eligibility criteria:
inclusion criteria: male and female children of 6 to less than 12 years of age, adolescents of 12 to less than 18 years of age and adults from 18 years: * scheduled for first cytotoxic chemotherapy cycle because of hematologic malignancies * and at intermediate or high risk of tls * and with no access to rasburicase exclusion criteria: * patients with contraindications as per febuxostat summary of product characteristics * patients with severe renal insufficiency * patients with severe hepatic insufficiency * patients with diagnosis of laboratory tls (ltls) or clinical tls (ctls)

Keywords: tls flo-02 hematological malignancies
special investigation (all cases) of lipacreon in patients with pancreatic exocrine insufficiency due to cystic fibrosis

Conditions: Cystic Fibrosis; Exocrine Pancreatic Insufficiency; Pancreatic Diseases; Digestive System Diseases

Summary: this study aims at collecting the information related to the safety and effectiveness in the pancreatic exocrine insufficiency patients due to cystic fibrosis receiving the treatment with lipacreon in order to evaluate the effective and safe use of lipacreon.


Eligibility criteria:
inclusion criteria * patients who receive lipacreon for the replacement of pancreatic digestive enzymes in pancreatic exocrine insufficiency due to cystic fibrosis exclusion criteria * patients with a history of hypersensitivity to the ingredient of lipacreon. * patients with a history of hypersensitivity to porcine protein

Keywords: digestive system diseases cystic fibrosis therapeutic uses gastrointestinal agents pancreatic diseases pancrelipase exocrine pancreatic insufficiency
effectiveness of analgesia in total knee arthroplasty

Conditions: Pain

Summary: the purpose of this study is to compare the analgesic effectiveness of three techniques: the femoral nerve block, intraarticular infiltration or a combination of both in the control of pain in total knee arthroplasty (ka). the hypothesis to be tested in this study is that the performance multimodal postoperative pain ka combining two analgesic techniques to obtain better analgesia than when applied separately.


Eligibility criteria:
inclusion criteria: * intervention program for total knee arthroplasty * asa i, ii, iii * over 65 years old exclusion criteria: * asa \> iii * patients who refuse the realization of technical loco-regional anesthesia * presence of coagulopathy or impaired hemostatic function * bmi \> 35 * serious intraoperative complications * patients undergoing bypass and aortic-femoral or femoro popliteal bypass operated leg * patients treated for chronic pain diagnosed processes, different knee osteoarthritis

Keywords: total knee arthroplasty intraarticular infiltration femoral block
patient-controlled sedation with propofol during cataract surgery under topical anesthesia

Conditions: Sedation

Summary: controversies exist about the use of propofol in sedation of patients for cataract surgery. this prospective randomised double-blind study evaluates the efficacy of patient-controlled sedation compared with placebo using the same device.


Eligibility criteria:
inclusion criteria: * patients should be operated of cataract under topical anesthesia exclusion criteria: * contra-indication to sedation * complicated cataract * hypersensitivity to propofol, known or suspected hypersensitivity to egg phospholipid, soybean or peanut protein * state of acute shock, severe dyslipidemia, severe liver failure, serious bleeding disorders * comprehension and language impairment * written and signed informed consent by the patient to participate in the study
photobiomodulation laser therapy for covid-19 positive patients with pulmonary disease

Conditions: COVID-19

Summary: the aim of this study is to evaluate the effectiveness of mls laser therapy as a treatment for pulmonary complications due to covid-19 infection.

participants will be randomized into treatment vs. control group. both groups will receive regular inpatient medical treatment. participants in the experimental arm will receive laser treatments once daily for 4 days. treatments will be delivered to the patients in a prone position using a 10 by 25 cm laser field across each lung with 7j/cm2 at 1500 hz. standard nursing protocols would be used to identify participant's pulmonary status throughout treatment.

Eligibility criteria:
inclusion criteria: * covid-19 positive * pulmonary compromise requiring oxygen support of approximately 2-6 liters * able to self prone, or support in self-sitting position exclusion criteria: * ventilator management * patients with autoimmune disorders or inflammatory conditions not related to covid-19 * pregnant women

Keywords: covid laser pulmonary